KPV (Lysine-Proline-Valine) is a naturally occurring tripeptide fragment derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH) that has drawn significant interest in immunological and gastroenterological research. Preclinical literature focuses heavily on its capacity to downregulate proinflammatory cytokine cascades without inducing systemic endocrine side effects. PX1 Research supplies analytical-grade KPV exclusively for qualified in vitro and animal model investigations.
KPV (Lysine-Proline-Valine) is a naturally occurring tripeptide fragment derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH) that has drawn significant interest in immunological and gastroenterological research. Preclinical literature focuses heavily on its capacity to downregulate proinflammatory cytokine cascades without inducing systemic endocrine side effects. PX1 Research supplies analytical-grade KPV exclusively for qualified in vitro and animal model investigations.
KPV peptide research examines the tripeptide sequence Lysine-Proline-Valine (Lys-Pro-Val), an active C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, KPV demonstrates potent anti-inflammatory properties by inhibiting NF-κB activation and modulating cytokine signaling within intestinal, cutaneous, and vascular endothelial cells, making it a primary candidate for studying mucosal barrier homeostasis and inflammatory bowel pathologies.
Unlike its parent hormone α-MSH, KPV does not bind to classical melanocortin receptors (MC1R–MC5R) with high affinity to stimulate pigment production or adrenal steroidogenesis. Instead, its cellular entry and signaling pathways appear to rely on specialized oligopeptide transporters, allowing investigators to isolate its anti-inflammatory mechanism from systemic hormonal responses. As a result, KPV peptide has emerged as a high-priority compound for evaluating targeted mucosal healing and inflammatory pathway suppression.
KPV is a tripeptide composed of L-lysine, L-proline, and L-valine residues linked via standard peptide bonds. Despite its small molecular weight (344.41 g/mol), the specific stereochemical arrangement of Lys-Pro-Val imparts notable stability against rapid enzymatic degradation compared to longer peptide chains. The proline residue provides a rigid structural turn, which isolates the terminal cationic lysine and hydrophobic valine groups in a conformation that optimizes cell-surface interactions.
In biological fluids and cell culture media, KPV demonstrates favorable stability profiles. Preclinical research indicates that KPV enters intracellular compartments primarily via PepT1 (SLC15A1), an H+-coupled oligopeptide transporter expressed prominently in the apical membrane of intestinal epithelial cells. Once inside the cell, KPV interacts directly with intracellular signaling nodes to modulate transcriptional machinery related to acute and chronic inflammatory cascades.
The primary mechanism identified in KPV research is its modulation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. NF-κB acts as a master transcriptional regulator for scores of proinflammatory genes, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS). In unstimulated states, NF-κB resides in the cytoplasm bound to the inhibitory protein IκB.
In vitro assays utilizing intestinal epithelial cell lines (such as Caco-2 and HT-29) and macrophage lineages demonstrate that KPV exposure inhibits the phosphorylation and degradation of IκB. By stabilizing IκB, KPV prevents the translocation of the p65 subunit of NF-κB into the nucleus. Preclinical data indicate that this nuclear blockade yields a marked reduction in downstream mRNA transcription of inflammatory cytokines, matrix metalloproteinases (MMPs), and adhesion molecules like ICAM-1. Researchers frequently utilize KPV in cell culture experiments to decipher how targeted peptide transporters can be exploited to arrest hyper-inflammatory intracellular signals.
A substantial portion of published KPV literature centers on gastrointestinal pathophysiology, specifically murine models of inflammatory bowel disease (IBD). In animal models of colitis induced by dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS), administration of KPV has been shown to attenuate histologic inflammation, suppress mucosal erosion, and preserve architectural integrity within the colon.
Mechanistically, KPV enhances intestinal barrier function by upregulating epithelial tight junction proteins, including zonula occludens-1 (ZO-1), occludin, and select claudin isoforms. Preclinical studies suggest that by restoring tight junction assembly, KPV decreases intestinal permeability (commonly referred to as 'leaky gut' in translational models), thereby limiting lumen-to-lamina-propria translocation of bacterial lipopolysaccharide (LPS). Research models evaluating mucosal healing often cross-reference KPV's performance against broader gut-modulating compounds documented across the PX1 research hub.
Beyond gastrointestinal research, KPV is widely studied in cutaneous inflammation models. In vitro experiments using human keratinocyte cultures (HaCaT cells) and rodent wound-healing assays demonstrate that KPV downregulates contact hypersensitivity reactions, UVB-induced erythema, and cutaneous edema. The tripeptide suppresses IL-8 secretion, reducing neutrophil infiltration into injured dermal tissue.
In addition to its anti-inflammatory signaling, preclinical literature identifies inherent antimicrobial properties for KPV. Research models investigating pathogen interactions show that KPV exhibits direct microbicidal activity against *Staphylococcus aureus* and *Candida albicans*. Investigators hypothesis that KPV enters microbial cells via transporter-mediated mechanisms, disrupting intracellular cellular functions or cell wall synthesis. This dual action—antimicrobial defense combined with anti-inflammatory modulation—makes KPV a frequent subject of study in wound healing and dermatological research.
When evaluating candidates for inflammation or tissue integrity models, researchers frequently compare KPV to other well-characterized peptides operating in similar physiological domains. Understanding the distinct receptor profiles and biochemical targets of each compound is essential for designing rigorous experimental controls.
While KPV functions largely through PepT1 transport and intracellular NF-κB modulation, BPC-157 research highlights systemic angiogenic acceleration, focal adhesion kinase (FAK) activation, and nitric oxide pathway regulation. Meanwhile, studies on Larazotide acetate focus almost exclusively on tight junction assembly through antagonism of zonulin signaling without direct antimicrobial activity. For studies requiring broad antimicrobial evaluation alongside immune modulation, investigators may also evaluate LL-37 research protocols. Selecting the appropriate compound depends on whether the laboratory objective is intracellular transcriptional arrest, structural barrier preservation, or direct pathogen neutralization.
To preserve structural integrity and prevent degradation, lyophilized KPV powder must be handled according to strict analytical protocol. Standard laboratory reconstitution involves dissolving the lyophilized cake in sterile, deionized water or phosphate-buffered saline (PBS, pH 7.4). For long-term cell culture studies where bacterial contamination must be strictly avoided, reconstituting with sterile-filtered buffers under a Class II laminar flow hood is standard practice.
Lyophilized KPV should be stored at -20°C or -80°C upon receipt, protected from light and moisture. Following reconstitution, working aliquots should be divided into single-use microcentrifuge tubes to prevent damage from repeated freeze-thaw cycles. Reconstituted aqueous solutions stored at 4°C are generally stable for short-term experimental windows (1–2 weeks), but freezing at -80°C is required for extended storage. Detailed handling documentation for diverse experimental setups can be found in our primary catalog of research peptides.
Experimental reproducibility in peptide research depends entirely on the chemical purity and batch consistency of the target molecule. Minor impurities, residual trifluoroacetic acid (TFA), or endotoxin contamination can confound in vitro cell viability assays and yield misleading transcriptomic or proteomic data. PX1 Research implements rigorous testing standards to verify every lot of KPV manufactured in our USA-based facilities.
Every batch of KPV undergoes High-Performance Liquid Chromatography (RP-HPLC) to confirm chromatographic purity above 98.0%, paired with Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight (344.41 Da). Crucially, because KPV is frequently applied to immunological and intestinal cell lines sensitive to lipopolysaccharide contamination, PX1 Research subjects all lots to Chromogenic Recombinant Factor C (rFC) or LAL endotoxin testing to guarantee levels below 0.01 EU/mg. Certificate of Analysis (COA) documents detailing lot traceability, HPLC traces, and mass spectra are available for all institutional accounts through our bulk peptide inquiries department.
What is the primary mechanism of KPV in cell culture research?
In preclinical cell culture models, KPV enters cells via the PepT1 transporter and inhibits the phosphorylation of IκB. This prevents the nuclear translocation of the p65 subunit of NF-κB, leading to reduced transcription of proinflammatory cytokines such as TNF-α, IL-6, and IL-1β.
Does KPV require specific transporters to enter target cells?
Yes, research indicates that KPV relies heavily on the PepT1 (SLC15A1) oligopeptide transporter for intracellular access, particularly in intestinal epithelial cells and skin keratinocytes.
What purity level is required for KPV in in vitro inflammatory assays?
For reliable in vitro and cell signaling research, KPV should possess a chemical purity of ≥98% as verified by RP-HPLC, with endotoxin levels strictly controlled below 0.01 EU/mg to prevent non-specific immune activation.
How does KPV differ from full-length alpha-MSH?
Full-length α-MSH is a 13-amino-acid tridecapeptide that activates melanocortin receptors (MC1R–MC5R), influencing pigmentation and endocrine functions. KPV is the C-terminal tripeptide fragment (Lys-Pro-Val) that retains anti-inflammatory activity without significant activation of classical melanocortin pigment receptors.
What solvent is recommended for reconstituting lyophilized KPV?
Lyophilized KPV is water-soluble and routinely reconstituted using sterile laboratory-grade water, phosphate-buffered saline (PBS, pH 7.4), or sterile bacteriostatic water, depending on the requirements of the downstream assay.
How should reconstituted KPV solutions be stored?
Reconstituted KPV should be aliquoted into single-use vials to avoid freeze-thaw cycles and stored at -20°C or -80°C. Short-term storage at 4°C is acceptable for up to two weeks.
Does KPV exhibit direct antimicrobial activity in laboratory settings?
Yes, preclinical studies report that KPV exhibits direct microbicidal activity against pathogens including Staphylococcus aureus and Candida albicans in specialized culture assays.
Where is PX1 Research KPV synthesized and tested?
PX1 Research synthesizes KPV in GMP-compliant facilities within the USA. Every lot undergoes independent ISO 17025 lab testing, including HPLC, Mass Spectrometry, and endotoxin verification before shipping from our California and Arizona logistics hubs.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.